Fareed, Jawed||Torri, Giangiacomo <br/><br/>
Looking Forward to the Future of Heparin: New Sources, Developments and Applications 

<br/><br/><br/>English[eng] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>alginate||n/a||edema||Heparin Red||solid lipid nanoparticles||Fe3O4·DA-BSA/HA||dermatan sulfate||sulfated alginate||porcine heparin||theranostics||low-molecular-weight heparin||Arixtra®||biomaterials||hepcidin||ovarian cancer||iron oxide nanoparticles||heparin-induced thrombocytopenia||bone morphogenetic protein (BMP)||hyaluronic acid (HA)||crude heparin||platelets||resistance||sclerostin||LMWH||gremlin||low molecular weight heparin (LMWH)||low molecular weight glycosaminoglycans||human plasma||single crystal X-ray structure||iron homeostasis||noggin||super paramagnetic iron oxide nanoparticles (SPION)||manufacturing methods||paclitaxel (PTX)||brain injury||bovine heparin||inflammation||qNMR||antithrombin||reference standard||quantitative NMR||enoxaparin||danaparoid sodium||NMR||GDNF||orthogonal multi-analytical methods||ternary complex||heparan sulphate||serglycin||bovine serum albumin (BSA)||HSQC||recombinant expression||heparin||heparin oligosaccharides||functional assay||BMP antagonists||intestinal lymphatic absorption||size exclusion chromatography||heparin coating||diagnosis||bioreactor||anemia||proteoglycan||heparin process||PCA||chemometric||fluorescent probe||pharmacopeia||affinity chromatography||component quantitative analysis||Fondaparinux sodium||perylene diimide dyes||thrombin inhibition||extended physicochemical characterization||cisplatin||glycosaminoglycans||TGF-?||chondroitin sulfate||dalteparin||sequence and compositional investigations||molecular weight||magnetic resonance imaging (MRI)||industrial||LC-MS||iduronic acid conformation||heparan sulfate||growth and differentiation factor (GDF)||assay||subarachnoid hemorrhage